MedWatch

EU migraine drug approval triggers multimillion-dollar bill for Lundbeck

When Lundbeck’s migraine treatment Vyepti was approved by the EU earlier this year, it passed a milestone – for Lundbeck itself, but also for investors in the drug’s original developer, who were now owed a total of USD 230m.

Photo: Piroschka Van De Wouw/Reuters/Ritzau Scanpix

More than two years after Lundbeck bought migraine drug Vyepti alongside the company behind it, Alder Biopharmaceuticals, which was publicly listed in the US before the acquisition, former investors can look forward to receiving the last bit of money they were promised.

In Lundbeck’s first quarterly report for 2022, which was released on Wednesday, the firm confirms that is has paid out around USD 230m related to Alder’s acquisition during the first quarter.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

In a world of options, Genmab's CEO chose partnerships

In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.

Analyst predicts slow start for Leo Pharma's Adtralza in UK

The take-up of Leo Pharma’s atopic eczema drug Adtralza in the UK will be slow-going, according to analyst bureau Global Data, after the British institute NICE released draft guidance where it was not recommend it as a standard treatment in England and Wales.

Further reading

Related articles

Latest news

See all jobs